Literature DB >> 9212749

Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage.

K Imai1, S Ohta, T Matsumoto, N Fujimoto, H Sato, M Seiki, Y Okada.   

Abstract

Matrix metalloproteinases (MMPs) are expressed in osteoarthritic (OA) cartilage and are thought to be involved in the degradation of cartilage extracellular matrix (ECM). Among these proteinases, MMP-2 (gelatinase A) demonstrates a wide range of substrate specificity against the ECM present in cartilage. Although MMP-2 expression increases in OA cartilage, the activation mechanism of the corresponding zymogen (pro-MMP-2) in cartilage is unknown. In this study, we examined the expression pattern of membrane-type 1 MMP (MT1-MMP) in human OA articular cartilage and its correlation with the activation of pro-MMP-2. Immunohistochemical studies demonstrate that MT1-MMP localizes to the chondrocytes in the superficial and transitional zones in all of the samples examined directly correlating with cartilage degradation. Reverse transcription polymerase chain reaction confirmed the predominant expression of MT1-MMP mRNA in the OA cartilage. In situ hybridization revealed the site of expression of MT1-MMP in OA cartilage to be the chondrocytes. Through gelatin zymography and a sandwich enzyme immunoassay it was demonstrated that OA cartilage explants secrete significantly higher levels of pro-MMP-2 than normal samples. Pro-MMP-2 activation was enhanced in the OA cartilage samples and correlated with MT1-MMP expression in the cartilage. Plasma membranes prepared from cultured chondrocytes with MT1-MMP expression and those directly isolated from OA cartilage could activate pro-MMP-2. MT1-MMP gene expression in cultured chondrocytes was induced by treatment with interleukin-1 alpha and/or tumor necrosis factor-alpha. These data suggest that cytokine-induced MT1-MMP in the chondrocytes may play a key role in the activation of pro-MMP-2 in the OA articular cartilage, leading to cartilage destruction through ECM degradation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212749      PMCID: PMC1857937     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data.

Authors:  H J Mankin; H Dorfman; L Lippiello; A Zarins
Journal:  J Bone Joint Surg Am       Date:  1971-04       Impact factor: 5.284

2.  Direct evidence for active metalloproteinases mediating matrix degradation in interleukin 1-stimulated human articular cartilage.

Authors:  J S Mort; G R Dodge; P J Roughley; J Liu; S J Finch; G DiPasquale; A R Poole
Journal:  Matrix       Date:  1993-03

3.  Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1.

Authors:  M Mohtai; R L Smith; D J Schurman; Y Tsuji; F M Torti; N I Hutchinson; W G Stetler-Stevenson; G I Goldberg
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

4.  Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein.

Authors:  Q Nguyen; G Murphy; C E Hughes; J S Mort; P J Roughley
Journal:  Biochem J       Date:  1993-10-15       Impact factor: 3.857

5.  The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B.

Authors:  A J Fosang; P J Neame; K Last; T E Hardingham; G Murphy; J A Hamilton
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

6.  Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation.

Authors:  D J Buttle; C J Handley; M Z Ilic; J Saklatvala; M Murata; A J Barrett
Journal:  Arthritis Rheum       Date:  1993-12

7.  A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies.

Authors:  N Fujimoto; N Mouri; K Iwata; E Ohuchi; Y Okada; T Hayakawa
Journal:  Clin Chim Acta       Date:  1993-11-30       Impact factor: 3.786

8.  Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay.

Authors:  A P Hollander; T F Heathfield; C Webber; Y Iwata; R Bourne; C Rorabeck; A R Poole
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

9.  Phenotypic stability of bovine articular chondrocytes after long-term culture in alginate beads.

Authors:  H J Häuselmann; R J Fernandes; S S Mok; T M Schmid; J A Block; M B Aydelotte; K E Kuettner; E J Thonar
Journal:  J Cell Sci       Date:  1994-01       Impact factor: 5.285

10.  Activity of type IV collagenases in benign and malignant breast disease.

Authors:  B Davies; D W Miles; L C Happerfield; M S Naylor; L G Bobrow; R D Rubens; F R Balkwill
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

View more
  14 in total

1.  Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis.

Authors:  Y T Konttinen; M Ainola; H Valleala; J Ma; H Ida; J Mandelin; R W Kinne; S Santavirta; T Sorsa; C López-Otín; M Takagi
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  RECK is up-regulated and involved in chondrocyte cloning in human osteoarthritic cartilage.

Authors:  Tokuhiro Kimura; Aiko Okada; Taku Yatabe; Masashi Okubo; Yoshiaki Toyama; Makoto Noda; Yasunori Okada
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

3.  The role of interleukin 6 in the pathophysiology of rheumatoid arthritis.

Authors:  Srinivasan Srirangan; Ernest H Choy
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-10       Impact factor: 5.346

4.  Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis.

Authors:  P K Petrow; D Wernicke; C Schulze Westhoff; K M Hummel; R Bräuer; J Kriegsmann; E Gromnica-Ihle; R E Gay; S Gay
Journal:  Ann Rheum Dis       Date:  2002-05       Impact factor: 19.103

5.  Expression of membrane-type 1 matrix metalloproteinase in rheumatoid synovial cells.

Authors:  S Honda; K Migita; Y Hirai; T Origuchi; S Yamasaki; M Kamachi; K Shibatomi; T Fukuda; M Kita; A Hida; H Ida; T Aoyagi; A Kawakami; Y Kawabe; K Oizumi; K Eguchi
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

6.  Membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan substrate rAgg1mut at the 'aggrecanase' and the MMP sites. Characterization of MT1-MMP catabolic activities on the interglobular domain of aggrecan.

Authors:  F H Büttner; C E Hughes; D Margerie; A Lichte; H Tschesche; B Caterson; E Bartnik
Journal:  Biochem J       Date:  1998-07-01       Impact factor: 3.857

7.  Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin(21-157).

Authors:  Vivian Berg; Baldur Sveinbjörnsson; Signy Bendiksen; Jan Brox; Khaled Meknas; Yngve Figenschau
Journal:  Arthritis Res Ther       Date:  2010-12-30       Impact factor: 5.156

Review 8.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

9.  Matrilin-3 induction of IL-1 receptor antagonist is required for up-regulating collagen II and aggrecan and down-regulating ADAMTS-5 gene expression.

Authors:  Chathuraka T Jayasuriya; Mary B Goldring; Richard Terek; Qian Chen
Journal:  Arthritis Res Ther       Date:  2012-09-11       Impact factor: 5.156

Review 10.  The role of changes in extracellular matrix of cartilage in the presence of inflammation on the pathology of osteoarthritis.

Authors:  Maricela Maldonado; Jin Nam
Journal:  Biomed Res Int       Date:  2013-08-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.